NCT01345734View on ClinicalTrials.gov

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

1,056

Participants

Timeline

Start Date

September 1, 2011

Primary Completion Date

July 26, 2013

Study Completion Date

July 26, 2013

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.

Trial Locations (1)

1605

Novo Nordisk Investigational Site, Manila

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01345734 - Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter